Weight Loss Could Save Billions in Healthcare Costs
Could Weight-Loss Drugs Save Billions in Healthcare Costs?
New research suggests dramatic weight loss achieved through medications like Wegovy and Zepbound could considerably reduce healthcare spending.
The Biden governance recently proposed covering GLP-1 weight-loss medications like Wegovy and Zepbound under Medicare and Medicaid,sparking debate about the drugs’ cost-effectiveness. Now, a new study published in JAMA Network Open adds fuel to the fire, suggesting that the substantial weight loss these medications can achieve could translate into massive savings for the U.S. healthcare system.
The study, led by Kenneth Thorpe, a professor of health policy at Emory University, found that a 25% reduction in weight among obese individuals could save an average of up to $5,442 per person annually. This level of weight loss is often seen in individuals using GLP-1 medications, according to the researchers.
“More than one-third of participating adults with overweight or obesity who used the [GLP-1] product lost 20% or more of their body weight,” Thorpe and his team noted. They argue that “improving access to new weight-loss medications, along with existing evidence-based behavior change and weight-loss interventions, should help reduce health care spending associated with obesity in the United States.”
The Obesity Epidemic and its Cost
The study’s findings are particularly timely given the alarming prevalence of obesity in the U.S. By 2020, an estimated 42% of Americans were obese, and another 31% were overweight. This means nearly three-quarters of all adults are not at a healthy weight.
The financial burden of this epidemic is staggering. It’s estimated that healthcare costs associated with obesity will reach $385 billion in 2024 alone.
Quantifying the Savings
To determine the potential savings from weight loss, Thorpe’s team analyzed data from nearly 3,800 Medicare recipients and over 13,400 adults with employer-sponsored insurance. All participants had a BMI of 25 or above, the threshold for being overweight.
The researchers found that even a modest 5% reduction in body weight could save $670 per year in healthcare costs for individuals with employer-sponsored insurance. This figure jumped to $2,849 for a 25% weight loss.
For Medicare recipients with at least one chronic illness, such as type 2 diabetes, heart disease, or arthritis, the annual savings for 5% and 25% weight loss were $1,262 and $5,442, respectively.
A Compelling Case for Coverage?
These findings paint a compelling picture of the potential financial benefits of weight loss, particularly through the use of GLP-1 medications.
“the projected annual savings from weight loss among U.S. adults with obesity were considerable for both Medicare and employer-based insurance,” Thorpe and his colleagues concluded. they believe their research will be of particular interest to employers,health plans,and Medicare as they grapple with the rising costs of obesity-related healthcare.
The debate over covering GLP-1 medications under Medicare and Medicaid is likely to continue. However, this new research adds a powerful economic argument to the discussion, suggesting that investing in weight loss interventions could ultimately save billions in healthcare spending.
Could Weight-Loss Drugs Save Billions in Healthcare Costs?
new research suggests dramatic weight loss achieved through medications like Wegovy and Zepbound could considerably reduce healthcare spending.
The Biden administration recently proposed covering GLP-1 weight-loss medications like Wegovy and Zepbound under Medicare and Medicaid, sparking debate about the drugs’ cost-effectiveness. Now, a new study published in JAMA Network Open adds fuel to the fire, suggesting that the substantial weight loss these medications can achieve could translate into massive savings for the U.S. healthcare system.
The study, led by Kenneth Thorpe, a professor of health policy at emory University, found that a 25% reduction in weight among obese individuals could save an average of up to $5,442 per person annually. This level of weight loss is frequently enough seen in individuals using GLP-1 medications, according to the researchers.
“More than one-third of participating adults with overweight or obesity who used the [GLP-1] product lost 20% or more of their body weight,” Thorpe and his team noted. They argue that “improving access to new weight-loss medications, along with existing evidence-based behavior change and weight-loss interventions, should help reduce health care spending associated with obesity in the United States.”
The Obesity Epidemic and its Cost
The study’s findings are particularly timely given the alarming prevalence of obesity in the U.S. By 2020, an estimated 42% of Americans were obese, and another 31% were overweight. This means nearly three-quarters of all adults are not at a healthy weight.
The financial burden of this epidemic is staggering.It’s estimated that healthcare costs associated with obesity will reach $385 billion in 2024 alone.
Quantifying the Savings
To determine the potential savings from weight loss, Thorpe’s team analyzed data from nearly 3,800 medicare recipients and over 13,400 adults with employer-sponsored insurance. All participants had a BMI of 25 or above, the threshold for being overweight.
The researchers found that even a modest 5% reduction in body weight could save $670 per year in healthcare costs for individuals with employer-sponsored insurance. This figure jumped to $2,849 for a 25% weight loss.
For Medicare recipients with at least one chronic illness, such as type 2 diabetes, heart disease, or arthritis, the annual savings for 5% and 25% weight loss were $1,262 and $5,442, respectively.
A Compelling Case for Coverage?
These findings paint a compelling picture of the potential financial benefits of weight loss, particularly through the use of GLP-1 medications.
“The projected annual savings from weight loss among U.S. adults with obesity were considerable for both Medicare and employer-based insurance,” Thorpe and his colleagues concluded. They believe their research will be of particular interest to employers, health plans, and Medicare as they grapple with the rising costs of obesity-related healthcare.
The debate over covering GLP-1 medications under Medicare and Medicaid is likely to continue. however, this new research adds a powerful economic argument to the discussion, suggesting that investing in weight loss interventions could ultimately save billions in healthcare spending.